FDA Proposes Mandatory Electronic Submission of AERs For Some Drugs
This article was originally published in The Tan Sheet
Executive Summary
FDA will require manufacturers to submit electronically adverse event reports for most drugs, biologics and devices, in order to identify post-marketing safety risks more quickly, cut costs and harmonize international reporting standards